PROF
Profound Medical Corp.
There isn't enough reported data to score PROF yet.
PROF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Unavailable | |
| Unavailable |
PROF's revenue is currently healthy, but its profitability is under pressure. There isn't enough data to rate its cash flow and balance sheet.
PROF PE Valuation
PROF has no meaningful PE right now: it lost money over the past year.
PROF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| Moderate |
Analysts expect PROF's losses to shrink, with revenue growing.
PROF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.93 | +$0.42 |
| Q2 2026 | -$0.98 | +$0.49 |
| Q1 2026 | -$1.24 | -$0.01 |
| Q4 2025 | -$1.41 | -$0.28 |
| Q3 2025 | -$1.35 | $0.00 |
| Q2 2025 | -$1.47 | -$0.24 |
| Q1 2025 | -$1.23 | +$0.07 |
| Q4 2024 | -$1.13 | +$0.23 |
PROF is still losing money, but less than at its worst: $0.93 per share over the past year, against $1.53 at its worst in early 2022.
PROF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $9.8M | +86% |
| Q2 2026 | $2.5M | +12% |
| Q1 2026 | $5.3M | +104% |
| Q4 2025 | $6M | +47% |
| Q3 2025 | $5.3M | +87% |
| Q2 2025 | $2.2M | -1% |
| Q1 2025 | $2.6M | +82% |
| Q4 2024 | $4.1M | +52% |
PROF's revenue has grown year over year for five quarters in a row: $10M last quarter, up 86% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -80% | +89 points |
| Q2 2026 | -446% | +179 points |
| Q1 2026 | -150% | +276 points |
| Q4 2025 | -123% | +77 points |
| Q3 2025 | -169% | +201 points |
| Q2 2025 | -624% | -273 points |
| Q1 2025 | -426% | +121 points |
| Q4 2024 | -200% | +2214 points |
PROF's operating margin was −80% last quarter, up 89 points from the same quarter a year ago.
PROF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$5M | +$4.6M |
| Q2 2026 | -$11.3M | +$2.4M |
| Q1 2026 | -$8.6M | -$300K |
| Q3 2025 | -$9.6M | -$2.8M |
| Q2 2025 | -$13.7M | -$7.5M |
| Q1 2025 | -$8.3M | -$3.8M |
| Q4 2024 | -$5.6M | +$1.4M |
| Q3 2024 | -$6.8M | -$2.5M |
PROF has burned cash in almost every quarter: −$35M over the past year, against −$34M the year before.
PROF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.6% | +205K shares |
| 1 year | +21% | +6.5M shares |
| 3 years | +71% | +15.2M shares |
| 5 years | +79% | +16.1M shares |
| Available history | +826% | +32.6M shares |
PROF has 37M diluted shares, up 21% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | — |
| Q1 2024 | — |
| Q4 2023 | — |
| Q3 2023 | — |
| Q2 2023 | — |
| Q1 2023 | — |
PROF Net Leverage
PROF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
PROF Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 57.6 | Neutral |
| Stochastic | 57.1 | Neutral |
PROF's weekly RSI is 58 (neutral) and its Stochastic is 57 (neutral).
PROF PE vs Healthcare Sector
PROF has no meaningful PE right now: it lost money over the past year.
PROF Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $6.41 | 16% above |
| 20 week MA | $6.65 | 12% above |
| 50 week MA | $6.77 | 9.9% above |
| 100 week MA | $6.31 | 18% above |
| 200 week MA | $7.97 | 6.6% below |
PROF has bounced recently, but its long-term trend is still down: it's above its 8-, 20-, 50- and 100-week averages, but 6.6% below its 200-week average.
PROF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $10.7 | $21.0 | +97% |
| 2021 | $21.0 | $11.7 | -45% |
| 2022 | $11.7 | $10.2 | -13% |
| 2023 | $10.2 | $8.49 | -17% |
| 2024 | $8.49 | $7.15 | -16% |
| 2025 | $7.15 | $7.37 | +3.1% |
| 2026 YTD | $7.37 | $7.44 | +0.9% |
PROF has finished lower in four of the last six years. It's up 0.9% so far in 2026.